Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123044) titled 'Flonoltinib Maleate for the treatment of patients with intermediate- or high-risk myelofibrosis who are refractory, relapsed, or intolerant to JAK inhibitors a single-arm, open-label, multicenter Phase IIb clinical trial evaluating efficacy and safety' on April 21.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University
Condition:
Myelofibrosis
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-30
Target Sample Size: Expe...